The Quantellect read.As of Nov 19, 2026, 7 active firms cover Immix Biopharma Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $19.00 to $30.00, a moderate spread. The average target of $24.14 sits 240% above the current $7.11. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.22 next quarter toward $-0.94 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$24.14
+239.6% upside
Average target across 7 active firms as of Nov 19, 2026 vs $7.11 current
Highest Target$30.00
Average Target$24.14
Lowest Target$19.00
Detailed analyst forecasts for IMMX
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate IMMX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IMMX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.22
Range $-0.26 – $-0.20 · 5 analysts · +24% YoY
Next period, 5 analysts expect Immix Biopharma Inc to earn $-0.22 a share (range $-0.26 – $-0.20), versus $-0.18 a year earlier. Full-year consensus is $-0.73, growing to $-0.94 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $33.4M next year.
Top analysts covering Immix Biopharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMMX.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$25.00+251.6% to target
Overall win rate
42%
+ Follow
#2
Graig Suvannavejh
Mizuho · Rank #239
Buy
$26.00+265.7% to target
Overall win rate
40%
+ Follow
#3
Gil Blum
Needham · Rank #409
Buy
$30.00+321.9% to target
Overall win rate
27%
+ Follow
#4
TA
Tazeen Ahmad
B of A Securities · Rank #411
Buy
$30.00+321.9% to target
Overall win rate
46%
+ Follow
#5
Reni J. Benjamin
JMP Securities · Rank #489
Buy
$23.00+223.5% to target
Overall win rate
29%
+ Follow
IMMX stock forecast FAQ
What is IMMX's average 12-month price target?+
The 7 active firms with a live target average $24.14 for Immix Biopharma Inc over the next 12 months, ranging from a $30.00 high to a $19.00 low, as of Nov 19, 2026.
Is IMMX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IMMX?+
The Street-high target is $30.00 (Needham), and the Street-low is $19.00 (Morgan Stanley). The average of all 7 active-firm targets is $24.14.
How many active Wall Street firms cover IMMX?+
7 active firms have a recognized rating on Immix Biopharma Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IMMX?+
Among analysts who currently cover IMMX, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #215). Their current call is Buy with a $25.00 target.
What is Immix Biopharma Inc's projected EPS for next quarter?+
The consensus estimate is $-0.22 per share (range $-0.26 – $-0.20) across 5 analysts. Full-year EPS is projected at $-0.73, rising to $-0.94 the following year.
How much revenue is Immix Biopharma Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $33.4M next year.
Have analysts been upgrading or downgrading IMMX lately?+
As of Nov 19, 2026, 7 of 7 active firms rate IMMX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMMX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.